News coverage about Voyager Therapeutics (NASDAQ:VYGR) has trended somewhat positive on Monday, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Voyager Therapeutics earned a media sentiment score of 0.00 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.8868153830237 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Voyager Therapeutics to Present at Investor Conferences in November (feeds.benzinga.com)
- Voyager Therapeutics to Host R&D Day on … (tmcnet.com)
- Voyager Therapeutics, Inc. (VYGR) Short Interest Up 44.9% in October (americanbankingnews.com)
- Voyager Therapeutics to Host R&D Day on November 16, 2017 (finance.yahoo.com)
- Zacks: Analysts Anticipate Voyager Therapeutics, Inc. (VYGR) to Announce -$0.76 EPS (americanbankingnews.com)
Shares of Voyager Therapeutics (NASDAQ:VYGR) traded up $0.17 during trading hours on Monday, reaching $13.60. 1,005,100 shares of the company were exchanged, compared to its average volume of 223,100. Voyager Therapeutics has a 52 week low of $8.10 and a 52 week high of $25.99.
In related news, insider Bernard Ravina sold 16,470 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.87, for a total value of $211,968.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 38,430 shares of company stock valued at $562,890 in the last three months. 8.00% of the stock is currently owned by insiders.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.